NeuroBlu v3.9.0 introduces targeted enhancements to refine and expand the capabilities of mental health research.

NeuroBlu v3.8 integrates a suite of comprehensive data features and our new NeuroBlu NLP psychotic disorders model for in-depth research.

In 2023, the NeuroBlu Database became the largest NLP-enriched, de-identified real-world data platform designed for mental and behavioral health.

NeuroBlu v3.6 now has over 4 million patients, a historic milestone in light of Holmusk's mission.

With updates like the MPR, NeuroBlu v3.5 paves the way for a more scalable system that captures a comprehensive patient journey.

NeuroBlu NLP transforms clinical notes into structured, analyzable, and actionable data not otherwise accessible in EHR or claims data.

The ability to refine and analyze custom cohorts and leverage common study designs is now powered by one feature - Cohort Explorer.

50% faster queries, 14k+ new patients and behavioral health clinical trials data to generate comparable RWD cohorts for analysis.

NeuroBlu v3.1 now includes improved clinical features and added ANSA & AIMS data elements. Refreshed data up to April 2023.

Improve analysis with autocomplete and project import in Code Studio. Updated data dictionary for better context on outcome measures.

A first-in-kind study analyzed real-world data from the NeuroBlu Database and found two predictors of psychiatric hospitalization that remained consistent across diagnoses, age, and sex.

Power up your analysis with NeuroBlu Database 23R1, a revamped homepage, enhanced Code Studio, and faster Cohort Builder.

New data sources, diagnostics symptoms, mental status exam data, and Cohort Builder criteria now available.

NeuroBlu enables study conducted to explore how symptoms of ADHD differ among genders.

Holmusk shares insights from a study conducted to understand how the COVID-19 pandemic impacted illness severity and healthcare utilization.

Explore cost-effective treatments with the new Economic Burden dashboard in Insights Explorer.

Holmusk's study sheds new light on the association between symptoms and hospitalization risk in people with behavioral health disorders.

New data with rich measurements, notifications on shared work, and updates to Insights Explorer.

NeuroBlu database powers Holmusk's natural language processing model specifically trained for behavioral health clinical data.

NeuroBlu enables study providing evidence on relationship between executive functioning and illness severity in patients with ADHD.

Holmusk shares real-world evidence generated using longitudinal behavioral health data on schizophrenia.

In this on-demand video we cover NeuroBlu’s recent milestone release which brings data and analytics tools to fuel your research.

Holmusk offers real-world evidence to shed new light on antipsychotic prescribing patterns.

In this on-demand video see how Insights Explorer can help uncover powerful information in just a few clicks.

Leveraging real-world data to generate new insights and answer pressing behavioral health questions.

NeuroDB 22R3 data release with new partners and measures along with project sharing in NeuroBlu.

Compare the impact of drugs in Insights Explorer and easily switch datasets.

Updated data architecture to enhance data quality and improve user experience.

New Insights Explorer feature for no-code exploration of real-world behavioral health data.

Improved Cohort Builder with index date and refined filtering on CGI-S measurements.

Improved data architecture for powerful analyses. Accelerate research by importing/exporting codes.

Recent progress and future plans on transforming behavioral health through real-world evidence.

NeuroBlu enables analysis of real-world data, in a secure and accessible environment, to answer challenging questions about behavioral health.

Holmusk shared findings from study investigating relationship between symptom burden and outcomes in patients with a diagnosis of schizophrenia.

Real-world data reveals differences between diagnoses and phenotypes, and how polypharmacy affects functioning in patients.

Holmusk offers new insights on the association between comorbid substance use disorders and illness severity in people with schizophrenia.

Holmusk offers new real-world evidence into patients with difficult-to-treat depression.

Holmusk publishes paper in BMJ Open, centering on dataset available in NeuroBlu, and platform capabilities.

Holmusk provides new insights into schizophrenia that could support more individualized care pathways.

Expanded dataset to enhance real-world impact. Boost efficiency with Help & Resources.

Filter search results and view data by categories. Download cohort visualizations to document your research.

Holmusk presents results from the largest analysis to date evaluating treatment of ADHD for young children.

Study uses Real-World Data to describe important patterns in the treatment of opioid use disorder.

Build dynamic risk models. New functions in Code Studio to conduct research studies faster.

Holmusk publishes abstract in American Academy of Child and Adolescent Psychiatry (AACAP) 68th Annual Meeting.

Enhanced experience with smoother onboarding journey, new CGI-S filter and new project organization tools.

Holmusk presents at American Society for Clinical Pathology (ASCP) 2021 Annual Meeting.

Holmusk invites start-ups and academics to submit proposals for projects using NeuroBlu.

Use Python to perform customized research studies on NeuroBlu.

Conduct advanced analytics with ease, with enhanced visualizations and documentation of research notes.